TRISALUS LIFE SCIENCES, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.72 USD | -3.38% |
|
-0.87% | -32.31% |
| 06-03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
| 05-30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 313.4 | 222.4 | 154.5 | - | - |
| Enterprise Value (EV) 1 | 313.4 | 222.4 | 154.5 | 154.5 | 154.5 |
| P/E ratio | -2.51 x | -1.26 x | -3.19 x | -4.37 x | -4.23 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 12 x | 5.35 x | 3.56 x | 2.58 x |
| EV / Revenue | - | 12 x | 5.35 x | 3.56 x | 2.58 x |
| EV / EBITDA | - | - | -3.84 x | -4.28 x | -4.84 x |
| EV / FCF | - | -4.39 x | -3.21 x | -3.21 x | -1.83 x |
| FCF Yield | - | -22.8% | -31.1% | -31.2% | -54.8% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 31,250 | 26,317 | 27,159 | - | - |
| Reference price 2 | 10.03 | 8.450 | 5.690 | 5.690 | 5.690 |
| Announcement Date | 4/21/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 18.51 | 28.88 | 43.41 | 60 |
| EBITDA 1 | - | - | -40.2 | -36.1 | -31.9 |
| EBIT 1 | - | -54.15 | -43.64 | -42.06 | -51.63 |
| Operating Margin | - | -292.53% | -151.07% | -96.9% | -86.05% |
| Earnings before Tax (EBT) 1 | - | -59.03 | -45.52 | -44.14 | -53.88 |
| Net income 1 | -47.19 | -63.28 | -46.39 | -44.58 | -54.31 |
| Net margin | - | -341.83% | -160.61% | -102.69% | -90.52% |
| EPS 2 | -3.990 | -6.730 | -1.783 | -1.303 | -1.347 |
| Free Cash Flow 1 | - | -50.63 | -48.1 | -48.19 | -84.61 |
| FCF margin | - | -273.53% | -166.51% | -111.02% | -141.02% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/21/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.721 | 6.457 | 6.894 | 7.355 | 8.197 | 9.514 | 10.45 |
| EBITDA 1 | - | - | -10.2 | -9.8 | -9.8 | -8.7 | -8.9 |
| EBIT 1 | -14.12 | -11.68 | -10.88 | -10.73 | -10.34 | -11.1 | -11.25 |
| Operating Margin | -246.78% | -180.97% | -157.85% | -145.85% | -126.11% | -116.64% | -107.64% |
| Earnings before Tax (EBT) 1 | -35.51 | -13.22 | -11.16 | -11.01 | -10.62 | -11.69 | -12.1 |
| Net income 1 | -36.31 | -14.02 | -11.26 | -11.11 | -10.75 | -12.34 | -12.25 |
| Net margin | -634.66% | -217.13% | -163.38% | -151.03% | -131.17% | -129.68% | -117.15% |
| EPS 2 | -1.560 | -0.6000 | -0.4600 | -0.4133 | -0.3700 | -0.3600 | -0.3450 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/1/24 | 5/15/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -50.6 | -48.1 | -48.2 | -84.6 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 1.44 | 2.18 | 2.65 |
| Capex / Sales | - | - | 4.99% | 5.02% | 4.41% |
| Announcement Date | 4/21/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.69
USD
Average target price
14.67
USD
Spread / Average Target
+157.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.31% | 155M | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| +8.24% | 23.61B | |
| -19.80% | 20.43B | |
| -16.19% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +66.67% | 15.19B | |
| +2.13% | 13.54B |
- Stock Market
- Equities
- TLSI Stock
- Financials TriSalus Life Sciences, Inc.
